In such therapy, the kinetics of the reduction of LDL andMDA-modified LDL levels virtually coincide attesting to the predominantutilization of oxidatively modified LDLs, indicating why the use of PCSK9 inpharmacotherapy of atherosclerosis seems to be so promising [104]. Here, PCSK9 is linked to atherosclerosis.